由于可供美国新冠肺炎患者使用的呼吸机严重不足,上周,医疗器械生产商美敦力祭出非常之举:开放自家呼吸机的生产技术,允许任何企业使用其技术生产呼吸机。
疫情当前,此举堪称果敢,对于一家习惯于保护自身知识产权的大企业而言尤其如此。美敦力表示,已收到大量想要获取呼吸机设计的申请。
美敦力开放技术的决定有助于缓解呼吸机短缺的问题,甚至可以在疫情期间成为其它企业效仿的榜样,从而提升其它医疗物资的生产速度。但专家也警告说此举可能带来难以预计的后果,美敦力用于分享呼吸机设计的许可证更是进一步加深了这种不确定性。
美敦力提供了什么
美敦力成立于1949年,总部位于美国明尼阿波利斯,生产从起搏器到胰岛素泵在内的多种医用产品,业务遍及140个国家和地区。上周,该公司宣布“为提升全球呼吸机生产速度,将分享自家呼吸机的设计规范”,作为全球医疗制造业的领头羊,这条消息迅速吸引了媒体注意。
为践行这一举措,美敦力已对外公布了一款呼吸机的设计图、电路图、源代码文件以及CAD软件设计参数。如果企业想获取前述文件,必须在美敦力的网站上完成注册,并同意其“许可授权”条款。
圣克拉拉大学知识产权研究专家、法学教授布莱恩·勒夫表示,该许可证与用于分发开源软件的许可证相似。他特别指出,美敦力在其许可证的“修改”部分要求,根据该公司的设计生产呼吸机的任何企业都必须持相同许可证进行销售。
理论上说,这意味着至少就目前而言,那些想要借助美敦力的技术生产呼吸机的企业无法要求客户支付专利费。
麦吉尔大学创新政策主管理查德·戈德表示,美敦力的许可证还有一个潜在问题,即到2024年10月,或世界卫生组织宣布大流行结束时,该许可便立即失效。
戈德表示,由于许可证的期限较短,可能会削弱企业加入到呼吸机生产行列的意愿。但他也补充道,这种许可证对那些只是想在疫情期间生产呼吸机的企业还是有用的。
戈德还指出,在美敦力的声明中并未明确说明将对外分享全部设计与数据,还是仅分享其中一部分。在被问及这一问题时,该公司拒绝做出回应。
总体而言,戈德称美敦力给出的许可证 “积极而又模糊”,并认为该许可证应该清楚写明,使用美敦力技术生产呼吸机的企业不得在呼吸机许可证到期后自行要求客户支付专利费。
戈德说:“我觉得,是美敦力某位高级副总裁为了更好的践行企业社会责任,决定对外开放呼吸机生产技术,然后这件事就到了律师团队手里,而在这种情况下,律师为了更好地保护公司的利益就设置了太多的条条框框,导致这一举措未能产生应有的效果。”
特斯拉的先例与效果
圣克拉拉大学教授勒夫认为,美敦力开放技术的举措与特斯拉首席执行官埃隆·马斯克在2014年采取开源政策颇为相似。当时,后者宣布将“开放”特斯拉的全部专利。通过此举,马斯克向世人表明特斯拉不会起诉任何使用该公司技术的企业,也为特斯拉做了一波宣传。勒夫表示,但就采用特斯拉技术的公司而言,该开源政策似乎并未对其造成任何长期影响
而美敦力此次通过“许可证”对外开放技术可能已经产生了实际影响。
美敦力公司发言人本·佩托克上周五告诉《财富》杂志:“截至目前,PB560型呼吸机的相关IP下载量已超过50,000个,而且这一数字每天还在增加。”
与此同时,据《明尼阿波利斯星论坛》上周四报道,为生产呼吸机,两家明尼苏达州的医疗器械生产厂家正在对美敦力的设计进行研究。几天前,埃隆·马斯克确认他正在与美敦力就呼吸机生产事宜进行沟通。
虽然美敦力开放技术的举措似乎已经有了一个好的开始,但也有人表示希望该公司能在技术分享方面更进一步。智囊机构R Street Institute的专利专家查尔斯·杜安表示,他希望美敦力能像IBM和微软等科技企业那样,不仅为技术开源贡献设计图纸,还能提供智囊支持。
杜安表示:“在我看来,美敦力开放自己现有的设计文档固然很好,但让其工程团队加入到诸多正在开展的开源呼吸机项目中可能更为重要。”(财富中文网)
译者:梁宇
审校:夏林
由于可供美国新冠肺炎患者使用的呼吸机严重不足,上周,医疗器械生产商美敦力祭出非常之举:开放自家呼吸机的生产技术,允许任何企业使用其技术生产呼吸机。
疫情当前,此举堪称果敢,对于一家习惯于保护自身知识产权的大企业而言尤其如此。美敦力表示,已收到大量想要获取呼吸机设计的申请。
美敦力开放技术的决定有助于缓解呼吸机短缺的问题,甚至可以在疫情期间成为其它企业效仿的榜样,从而提升其它医疗物资的生产速度。但专家也警告说此举可能带来难以预计的后果,美敦力用于分享呼吸机设计的许可证更是进一步加深了这种不确定性。
美敦力提供了什么
美敦力成立于1949年,总部位于美国明尼阿波利斯,生产从起搏器到胰岛素泵在内的多种医用产品,业务遍及140个国家和地区。上周,该公司宣布“为提升全球呼吸机生产速度,将分享自家呼吸机的设计规范”,作为全球医疗制造业的领头羊,这条消息迅速吸引了媒体注意。
为践行这一举措,美敦力已对外公布了一款呼吸机的设计图、电路图、源代码文件以及CAD软件设计参数。如果企业想获取前述文件,必须在美敦力的网站上完成注册,并同意其“许可授权”条款。
圣克拉拉大学知识产权研究专家、法学教授布莱恩·勒夫表示,该许可证与用于分发开源软件的许可证相似。他特别指出,美敦力在其许可证的“修改”部分要求,根据该公司的设计生产呼吸机的任何企业都必须持相同许可证进行销售。
理论上说,这意味着至少就目前而言,那些想要借助美敦力的技术生产呼吸机的企业无法要求客户支付专利费。
麦吉尔大学创新政策主管理查德·戈德表示,美敦力的许可证还有一个潜在问题,即到2024年10月,或世界卫生组织宣布大流行结束时,该许可便立即失效。
戈德表示,由于许可证的期限较短,可能会削弱企业加入到呼吸机生产行列的意愿。但他也补充道,这种许可证对那些只是想在疫情期间生产呼吸机的企业还是有用的。
戈德还指出,在美敦力的声明中并未明确说明将对外分享全部设计与数据,还是仅分享其中一部分。在被问及这一问题时,该公司拒绝做出回应。
总体而言,戈德称美敦力给出的许可证 “积极而又模糊”,并认为该许可证应该清楚写明,使用美敦力技术生产呼吸机的企业不得在呼吸机许可证到期后自行要求客户支付专利费。
戈德说:“我觉得,是美敦力某位高级副总裁为了更好的践行企业社会责任,决定对外开放呼吸机生产技术,然后这件事就到了律师团队手里,而在这种情况下,律师为了更好地保护公司的利益就设置了太多的条条框框,导致这一举措未能产生应有的效果。”
特斯拉的先例与效果
圣克拉拉大学教授勒夫认为,美敦力开放技术的举措与特斯拉首席执行官埃隆·马斯克在2014年采取开源政策颇为相似。当时,后者宣布将“开放”特斯拉的全部专利。通过此举,马斯克向世人表明特斯拉不会起诉任何使用该公司技术的企业,也为特斯拉做了一波宣传。勒夫表示,但就采用特斯拉技术的公司而言,该开源政策似乎并未对其造成任何长期影响
而美敦力此次通过“许可证”对外开放技术可能已经产生了实际影响。
美敦力公司发言人本·佩托克上周五告诉《财富》杂志:“截至目前,PB560型呼吸机的相关IP下载量已超过50,000个,而且这一数字每天还在增加。”
与此同时,据《明尼阿波利斯星论坛》上周四报道,为生产呼吸机,两家明尼苏达州的医疗器械生产厂家正在对美敦力的设计进行研究。几天前,埃隆·马斯克确认他正在与美敦力就呼吸机生产事宜进行沟通。
虽然美敦力开放技术的举措似乎已经有了一个好的开始,但也有人表示希望该公司能在技术分享方面更进一步。智囊机构R Street Institute的专利专家查尔斯·杜安表示,他希望美敦力能像IBM和微软等科技企业那样,不仅为技术开源贡献设计图纸,还能提供智囊支持。
杜安表示:“在我看来,美敦力开放自己现有的设计文档固然很好,但让其工程团队加入到诸多正在开展的开源呼吸机项目中可能更为重要。”(财富中文网)
译者:梁宇
审校:夏林
As the U.S. faces a critical shortage of ventilators for coronavirus patients, medical device maker Medtronic stepped up with an unusual offer last week: It would share its ventilator technology and allow any company to manufacture it.
It was a bold gesture during a crisis, especially for a giant corporation accustomed to guarding its intellectual property. And Medtronic says it has already received a large number of requests for its ventilator designs.
The company's decision to open up its technology could help alleviate the ventilator shortage and even provide a model to increase production of other medical supplies during the crisis. Experts, however, caution that such an outcome is far from certain, especially in light of the license Medtronic is using to share its ventilators.
What Medtronic is offering
Founded in 1949, Minneapolis-based Medtronic makes products ranging from pacemakers to insulin pumps and operates in 140 countries. The company's sheer scale is one reason the media took notice when it announced last week that it would "share ventilation design specifications to accelerate efforts to increase global ventilator production."
In practice, this led Medtronic to share blueprints for one of its ventilator models, as well as circuit board drawings, files of source code, and CAD software designs. In order to access all this, companies must register on Medtronic's website and agree to the terms of a "permissive license."
According to Brian Love, a law professor at Santa Clara University who specializes in intellectual property, the license in question is reminiscent of those used to distribute open-source software. He points in particular to the "Modifications" section of Medtronic's license, which requires anyone who makes a ventilator based on the company's designs to distribute it under an identical license.
In theory, this means that those who decide to build on Medtronic's technology can't turn around and force customers to pay intellectual-property royalties—at least for now.
According to Richard Gold, an authority on innovation policy at McGill University, a potential hitch in the Medtronic license is that it's in force only until October 2024 or whenever the World Health Organization declares the pandemic to be over.
This means, says Gold, that some companies may be reluctant to start making the ventilators because of the short term of the license. He added, however, that firms seeking to enter the ventilator field just for the duration of the crisis would find the license to be useful.
Gold also noted that Medtronic was unclear in its announcement about whether it was sharing all of its designs and data or only some of it. The company declined to answer a question about that point.
Overall, Gold described the license as "positive but vague" and said it should have been written to ensure those using Medtronic's technology can't themselves demand intellectual-property royalties after the ventilator license expires.
"My feeling is that a senior VP decided to make the technology available as part of good corporate responsibility, and then it went to the lawyers who, in an attempt to protect the company too much given the circumstances, made the gesture less effective than it could have been," said Gold.
A Tesla precedent and early response
Love, the Santa Clara professor, likened the Medtronic initiative to a similar gesture in 2014 by Tesla CEO Elon Musk, who announced he would "open up" the company's patents. That initiative, which amounted to Musk saying Tesla would not sue anyone for using its tech, provided a wave of publicity for the company. But it also did not appear to have any long-term effect in terms of other companies adopting the technology, says Love.
In the case of Medtronic, though, it appears the company's "permissive license" offer may already be having a real-world impact.
"There have been more than 50,000 downloads so far of the IP associated with the PB560 [ventilator] and more every day," Medtronic spokesperson Ben Petok told Fortune on Friday.
Meanwhile, the Minneapolis Star Tribune reported on Thursday that two medical manufacturers in Minnesota were studying the Medtronic designs with the intention of making ventilators. And days earlier, Elon Musk confirmed he was in talks with Medtronic to produce the products.
While the Medtronic initiative appears to be off to a promising start, others expressed hope the company would go even further to promote technology sharing. Charles Duan, a patent expert at think tank R Street Institute, said he would like to see Medtronic follow the example of tech firms like IBM and Microsoft, which have contributed not just blueprints, but brainpower, to open-source initiatives.
"What would be more significant in my mind is if Medtronic makes available not just its existing designs but also its engineering team, to contribute to the many ongoing open-source ventilator projects," said Duan.